Gebhardt C - Search Results

1

Leukocyte count restoration under dabrafenib treatment in a melanoma patient with vemurafenib-induced leukopenia: case report.

Orouji E, Ziegler B, Umansky V, Gebhardt C, Utikal J. Orouji E, et al. Among authors: gebhardt c. Medicine (Baltimore). 2014 Dec;93(28):e161. doi: 10.1097/MD.0000000000000161. Medicine (Baltimore). 2014. PMID: 25526431 Free PMC article.

2

Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.

Gebhardt C, Staub J, Schmieder A, Goerdt S, Utikal J. Gebhardt C, et al. Acta Derm Venereol. 2015 Jan;95(1):96-7. doi: 10.2340/00015555-1869. Acta Derm Venereol. 2015. PMID: 24710689 Free article. No abstract available.

3

Efficacy of vemurafenib in a trametinib-resistant stage IV melanoma patient--letter.

Bernhardt M, Orouji E, Larribere L, Gebhardt C, Utikal J. Bernhardt M, et al. Among authors: gebhardt c. Clin Cancer Res. 2014 May 1;20(9):2498-9. doi: 10.1158/1078-0432.CCR-13-2349. Clin Cancer Res. 2014. PMID: 24789037 No abstract available.

4

Complete remission of treatment-refractory advanced angiosarcoma of the scalp by protracted intralesional interleukin-2 therapy.

Gebhardt C, Ziegler B, Stadler S, Goerdt S, Utikal J. Gebhardt C, et al. Br J Dermatol. 2015 Apr;172(4):1156-8. doi: 10.1111/bjd.13400. Epub 2015 Feb 25. Br J Dermatol. 2015. PMID: 25204400 No abstract available.

5

Myeloid-derived suppressor cells in malignant melanoma.

Umansky V, Sevko A, Gebhardt C, Utikal J. Umansky V, et al. Among authors: gebhardt c. J Dtsch Dermatol Ges. 2014 Nov;12(11):1021-7. doi: 10.1111/ddg.12411. Epub 2014 Sep 28. J Dtsch Dermatol Ges. 2014. PMID: 25263083 Review. English, German.

6

Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.

Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, Umansky V. Jiang H, et al. Among authors: gebhardt c. Int J Cancer. 2015 May 15;136(10):2352-60. doi: 10.1002/ijc.29297. Epub 2014 Nov 12. Int J Cancer. 2015. PMID: 25353097

7

New therapeutic options for advanced non-resectable malignant melanoma.

Stadler S, Weina K, Gebhardt C, Utikal J. Stadler S, et al. Among authors: gebhardt c. Adv Med Sci. 2015 Mar;60(1):83-8. doi: 10.1016/j.advms.2014.12.002. Epub 2014 Dec 25. Adv Med Sci. 2015. PMID: 25596540 Review.

8

Diminished levels of the soluble form of RAGE are related to poor survival in malignant melanoma.

Wagner NB, Weide B, Reith M, Tarnanidis K, Kehrel C, Lichtenberger R, Pflugfelder A, Herpel E, Eubel J, Ikenberg K, Busch C, Holland-Letz T, Naeher H, Garbe C, Umansky V, Enk A, Utikal J, Gebhardt C. Wagner NB, et al. Among authors: gebhardt c. Int J Cancer. 2015 Dec 1;137(11):2607-17. doi: 10.1002/ijc.29619. Epub 2015 Jul 14. Int J Cancer. 2015. PMID: 26018980 Free article.

9

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.

Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, Holland-Letz T, Umansky L, Beckhove P, Sucker A, Schadendorf D, Utikal J, Umansky V. Gebhardt C, et al. Clin Cancer Res. 2015 Dec 15;21(24):5453-9. doi: 10.1158/1078-0432.CCR-15-0676. Epub 2015 Aug 19. Clin Cancer Res. 2015. PMID: 26289067

10

MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma.

Orouji E, Orouji A, Gaiser T, Larribère L, Gebhardt C, Utikal J. Orouji E, et al. Among authors: gebhardt c. Int J Cancer. 2016 May 1;138(9):2257-62. doi: 10.1002/ijc.29970. Epub 2016 Jan 11. Int J Cancer. 2016. PMID: 26684394

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

495 results

Search Page

Filters